Patients with advanced blood cancer respond to treatment with Agios' AG-221, according to study results presented Sunday.
The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. The selling has gained in volume and speed as no one wants to be the last trader standing.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Northwest Bio is now acknowledging that no agreement with the FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.
Tuesday's FDA panel voted overwhelmingly to support the approval of Mannkind's inhaled insulin Afrezza.
TheStreet's biotech columnist Adam Feuerstein is providing live play-by-play of today's FDA advisory panel for Mannkind's inhaled insulin.
TheStreet's Adam Feuerstein sets the table for Mannkind and its inhaled, rapid-acting insulin Afrezza ahead of Tuesday's FDA advisory panel meeting.
The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.